Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.7.4279

Tyrosine 1045 Codon Mutations in Exon 27 of EGFR are Infrequent in Oral Squamous Cell Carcinomas  

Tushar, Mehta Dhaval (Human Genetics Laboratory, Sree Balaji Medical and Dental College and Hospital, Bharath University)
Ramanathan, Arvind (Human Genetics Laboratory, Sree Balaji Medical and Dental College and Hospital, Bharath University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.7, 2013 , pp. 4279-4282 More about this Journal
Abstract
Background: The activation and inactivation of receptor tyrosine kinases are tightly regulated to ensure faithful replication of cells. After having transduced extracellular growth activating signals, activated EGFR is subjected to downregulation either by clathrin mediated endocytosis or c-Cbl mediated proteasome degradation depending on the ligand concentration. c-Cbl is an ubiquitin ligase which requires a phosphorylated tyrosine residue at position 1045 in the cytoplasmic domain of EGFR to interact and add ubiquitin molecules. While activating mutations in exons 19 and 21 have been associated with the development of several cancers, the status of mutations at tyrosine 1045 coding exon 27 of EGFR remain to be investigated. Consistently, defective phosphorylation at 1045 has been associated with sustained phosphorylation of EGFR in non-small lung carcinomas. Hence in the present study we investigated the genetic status of the tyrosine 1045 coding site within exon 27 of EGFR gene to explore for possible occurrence of mutations in this region, especially since no studies have addressed this issue so far. Materials and Methods: Tumor chromosomal DNA isolated from thirty five surgically excised oral squamous cell carcinoma tissues was subjected to PCR amplification with intronic primers flanking the tyrosine 1045 coding exon 27 of EGFR gene. The PCR amplicons were subsequently subjected to direct sequencing to elucidate the mutation status. Results: Sequence analysis identified no mutations in the tyrosine 1045 codon of EGFR in any of the thirty five samples that were analyzed. Conclusions: The lack of identification of mutation in the tyrosine 1045 codon of EGFR suggests that mutations in this region may be relatively rare in oral squamous cell carcinomas. To the best of our knowledge, this study is the first to have explored the genetic status of exon 27 of EGFR in oral squamous cell carcinoma tissue samples.
Keywords
EGFR expression in oral carcinoma; tyrosine 1045 mutation; tyrosine 1045 phosphorylation;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Abella JV, Park M (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab, 296, 973-84.   DOI   ScienceOn
2 Burgess AW (2008). EGFR family: structure physiology signaling and therapeutic targets. Growth Factors, 26, 263-74.   DOI   ScienceOn
3 Castillo L, Etienne-Grimaldi MC, Fischel JL, et al (2004). Pharmacological background of EGFR targeting. Ann Oncol, 15, 1007-12.   DOI   ScienceOn
4 de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J (2001). c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytotic route. J Cell Science, 114, 2167-78.
5 de Melker AA, van der Horst G, Borst J (2004). Ubiquitin ligase activity of c-Cbl guides the epidermal growth factor receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J Biol Chem, 279, 55465-73.   DOI   ScienceOn
6 El-Rayes BF, LoRusso PM (2004). Targeting the epidermal growth factor receptor. Bri J Cancer, 91, 418-24.   DOI   ScienceOn
7 Fukazawa T, Miyake S, Bandi V, Band H (1996). Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) Stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem, 271, 14554-9.   DOI   ScienceOn
8 Glogowska A, Stetefeld J, Weber E, et al (2012). Epidermal growth factor cytoplasmic domain affects erbb protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells. Neoplasia, 14, 336-409.
9 Han W, Zhang T, Yu H, Foulke JG, Tang CK (2006). Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther, 5, 1361-8.   DOI
10 Hosaka T, Inoue F, Ando K, et al (2007). Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. Anticancer Res, 27, 2253-64.
11 Huang F, Sorkin A (2005). Growth factor receptor binding protein 2 mediated recruitment of the RING domain of Cbl to the epidermal growth factor receptor is essential and sufficient to support receptor endocytosis. Mol Biol Cell, 16, 1268-81.   DOI   ScienceOn
12 Huang F, Goh LK, Sorkin A (2007). EGF receptor ubiquitination is not necessary for its internalization. PNAS, 104, 16904-9.   DOI   ScienceOn
13 Jayaraman B, Valiathan GM, Jayakumar K, et al (2012). Lack of mutation in p53 and H-ras genes in phenytoin induced gingival overgrowth suggests its non cancerous nature. Asian Pac J Cancer Prev, 13, 5535-8.   DOI   ScienceOn
14 Kim YT, Park SW, Kim JW (2002). Correlation between expression of EGFR and the prognosis of patients with cervical cancer. Gynecol Oncol, 87, 84-9.   DOI   ScienceOn
15 Kirisits A, Pils D, Krainer M (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. nt J Biochem Cell Biol, 39, 2173-82.   DOI   ScienceOn
16 Kirkegaard T, Jaattela M (2009). Lysosomal involvement in cell death and cancer. Biochim Biophys Acta, 1793, 746-54.   DOI   ScienceOn
17 Leahy DJ (2004). Structure and Function of the Epidermal Growth Factor (egf/erbb) family of receptors. Adv Protein Chem, 68, 1-27.   DOI   ScienceOn
18 Lipkowitz S (2002). The role of the ubiquitination-proteasome pathway in breast cancer Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res, 5, 8-15.   DOI
19 McMillen E, Ye F, Li G, Wu Y, Kin G et al (2010). Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res, 36, 531-7.   DOI   ScienceOn
20 Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S et al (2010). Heterozygous germline mutations in the CBL tumorsuppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet, 87, 250-7.   DOI   ScienceOn
21 Murugan AK, Munirajan AK, Tsuchida N (2012). Ras oncogenes in oral cancer: the past 20 years. Oral Oncol, 48, 383-92.   DOI   ScienceOn
22 Normanno N, De Luca A, Bianco C, et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 336, 2-16.
23 Ogiso H, Ishitani R, Nureki O, et al (2002). Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell, 110, 775-87.   DOI   ScienceOn
24 Pennock S, Wang Z (2008). A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Molecular and Cell Biology, 28, 3020-37.   DOI   ScienceOn
25 Rajendran S, Muthupalani RS, Ramanathan A (2013). Lack of RING finger domain (RFD) Mutations of the c-Cbl gene in oral squamous cell carcinomas in Chennai, India. Asian Pac J Cancer Prev, 14, 1073-5.   DOI   ScienceOn
26 Rubin C, Gur G, Yarden Y (2005). Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res, 15, 66-71.   DOI   ScienceOn
27 Sigismund S, Confalonieri S, Ciliberto A, et al (2012). Endocytosis and signaling: cell logistics shape the eukaryotic cell plan. Physiol Rev, 92, 273-366.   DOI   ScienceOn
28 Soonthornthum T, Arias-Pulido H, Joste N, et al (2011). Epidermal growth factor receptor as a biomarker for cervical cancer. Ann Oncol, 10, 2166-78.
29 Visser Smit GD, Place TL, Cole SL, et al (2009). Cbl controls EGFR fate by regulating early endosome. Sci Signal, 2, 86.
30 Valiathan GM, Thenumgal SJ, Jayaraman B, et al (2012). Common docking domain mutation E322K of the ERK2 gene is infrequent in oral squamous cell carcinomas. Asian Pac J Cancer Prev, 13, 6155-7.   DOI   ScienceOn
31 Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Annals of Oncology, 8, 1197-206.   DOI   ScienceOn
32 Woelk T, Sigismund S, Penengo L, Polo S (2007). The ubiquitination code: a signalling problem. Cell Division, 2, 11.   DOI